<p>Neurocrine Biosciences, Inc.（纳斯达克股票代码：NBIX）内部人员 Ingrid Delaet 于 8 月 13 日星期二进行了交易，卖出了公司股票 7143 股。股票平均售价为 150.10 美元，总价值为 1072164.30 美元。交易后，该内部人员持有公司股票 2507 股，价值 376300.70 美元。该交易已在提交给证券交易委员会的法律文件中披露，可通过此链接查看。</p>
<p>获取 <strong>Neurocrine Biosciences</strong> 警报：</p>
<ul>
<li>百时美施贵宝的大举动：斥资 181 亿美元进行 2 笔生物科技交易</li>
</ul>
<p>Ingrid Delaet 最近还进行了以下交易：</p>
<ul>
<li>8 月 6 日星期二，Ingrid Delaet 卖出了 Neurocrine Biosciences 股票 273 股。股票平均售价为 147.70 美元，总价值为 40322.10 美元。</li>
</ul>
<h2>Neurocrine Biosciences 股价表现</h2>
<p>NBIX 周四午盘交易上涨 1.08 美元，报价 147.77 美元。公司股票交易量为 720,170 股，相比平均交易量 819,548 股。该公司的 50 天移动平均价为 141.47 美元，200 天移动平均价为 138.88 美元。该股市值为 148.7 亿美元，市盈率为 40.55，β系数为 0.37。Neurocrine Biosciences, Inc.的 52 周最低价为 103.63 美元，52 周最高价为 157.98 美元。</p>
<ul>
<li>在强劲的第三季度报告后，中型市值的 Neurocrine Biosciences 值得买入吗？</li>
</ul>
<p>Neurocrine Biosciences（纳斯达克股票代码：NBIX）于 8 月 1 日星期四发布了季度财报。公司报告该季度每股收益为 0.63 美元，低于分析师预期的 1.15 美元（低 0.52 美元）。该季度营收为 5.902 亿美元，超过预期的 5.4598 亿美元。Neurocrine Biosciences 的净利润率为 16.00%，净资产收益率为 14.86%。公司该季度的营收同比增长 30.4%。在去年同期，公司每股收益为 0.95 美元。卖方分析师预测，Neurocrine Biosciences, Inc.今年将实现每股收益 4.22 美元。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近对该公司的持股进行了调整。RFP Financial Group LLC 在第一季度将其对 Neurocrine Biosciences 的持股增加了 346.5%。RFP Financial Group LLC 现在拥有该公司股票 192 股，价值 26000 美元，上季度购入了额外的 149 股。Mather Group LLC 在第一季度购入了新的 Neurocrine Biosciences 股票，价值 26000 美元。Ashton Thomas Private Wealth LLC 在第二季度购入了新的 Neurocrine Biosciences 股票，价值 28000 美元。Lindbrook Capital LLC 在第四季度将其对 Neurocrine Biosciences 的持股增加了 85.0%。Lindbrook Capital LLC 现在拥有该公司股票 209 股，价值 28000 美元，上季度购入了额外的 96 股。最后，Innealta Capital LLC 在第二季度购入了新的 Neurocrine Biosciences 股票，价值 30000 美元。对冲基金和其他机构投资者拥有该公司股票的 92.59%。</p>
<h2>华尔街分析师观点</h2>
<p>NBIX 近期成为多家分析师关注的对象。Oppenheimer 将 Neurocrine Biosciences 的目标股价从 216.00 美元上调至 219.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “表现优异” 评级。摩根大通将 Neurocrine Biosciences 的股票价格目标从 173.00 美元上调至 181.00 美元，并在 8 月 7 日星期三的研究报告中给予该股票 “超配” 评级。Wedbush 在 5 月 29 日星期三的研究报告中重申了对 Neurocrine Biosciences 的 “表现优异” 评级，并设定了 152.00 美元的股价目标。摩根士丹利将 Neurocrine Biosciences 的股票价格目标从 160.00 美元上调至 170.00 美元，并在 7 月 12 日星期五的研究报告中给予该股票 “超配” 评级。最后，康泰纳菲茨重申了对 Neurocrine Biosciences 的 “超配” 评级，并在 7 月 25 日星期四的研究报告中设定了 155.00 美元的股价目标。六位研究分析师对该股票给予持有评级，十六位给予买入评级，两位给予强烈买入评级。根据 MarketBeat 的数据，Neurocrine Biosciences 目前的共识评级为 “中度买入”，共识目标股价为 158.68 美元。</p>
<p>获取我们关于 Neurocrine Biosciences 的最新研究报告</p>
<h2>Neurocrine Biosciences 公司简介</h2>
<p>Neurocrine Biosciences, Inc.是一家在美国和国际市场上为神经、神经内分泌和神经精神疾病研发和销售药物的公司。该公司的产品包括用于迟发性运动障碍和与亨廷顿病相关的舞蹈症的 INGREZZA；用于肾上腺功能不全的 ALKINDI；用于经典先天性肾上腺增生的 Efmody 胶囊；用于子宫内膜异位症的 Orilissa 片剂；以及用于治疗子宫肌瘤的 Oriahnn 胶囊。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票胜过 Neurocrine Biosciences</li>
<li>什么是股息？购买最佳股息股票</li>
<li>迈克尔·伯里的阿里巴巴赌注及其对整个市场的影响</li>
<li>风险承受能力，一刀切并不适合所有人</li>
<li>杰夫·布朗的 Exegesis AI 股票推荐</li>
<li>在 52 周最低点找到并盈利交易股票</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔哈撒韦买入了 Ulta 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA"/></p>
<p><em>此即时新闻警报由 narrative science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ ⭕ [紧急] 刚刚触发购买警报（来自市场幕后）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2"/></p>
<h2>现在是否值得投资神经分泌生物科学（Neurocrine Biosciences）？</h2>
<p>在考虑投资神经分泌生物科学之前，您可能需要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票... 而神经分泌生物科学并不在这个名单上。</p>
<p>尽管神经分泌生物科学目前在分析师中有一个 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

神经分泌生物科学

<p>英格丽德拉特是神经分泌生物科学公司（NASDAQ: NBIX）的内部人士，于 8 月 13 日出售了 7,143 股，金额约为 2,072,164.30 美元，剩余 2,507 股价值约 79,300 美元。这笔交易已在提交给美国证券交易委员会（SEC）的文件中披露。此外，NBIX 股票最近经历了波动，分析师对该股持有不同意见，一些人认为股票具有 “中等买入” 共识，目标价位在 55-65 美元的范围内</p>

<p>Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 7,143 shares of the business's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.10, for a total value of $1,072,164.30. Following the transaction, the insider now owns 2,507 shares of the company's stock, valued at $376,300.70. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Neurocrine Biosciences, Inc.（纳斯达克股票代码：NBIX）内部人员 Ingrid Delaet 于 8 月 13 日星期二进行了交易，卖出了公司股票 7143 股。股票平均售价为 150.10 美元，总价值为 1072164.30 美元。交易后，该内部人员持有公司股票 2507 股，价值 376300.70 美元。该交易已在提交给证券交易委员会的法律文件中披露，可通过此链接查看。</p>
</div><p>Get <strong>Neurocrine Biosciences</strong> alerts:</p>
<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Neurocrine Biosciences</strong> 警报：</p>
<ul>
<li>百时美施贵宝的大举动：斥资 181 亿美元进行 2 笔生物科技交易</li>
</ul>
</div><p>Ingrid Delaet also recently made the following trade(s):</p>
<ul>
<li>On Tuesday, August 6th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $147.70, for a total value of $40,322.10.</li>
</ul>
<div class="lb-trans"><p>Ingrid Delaet 最近还进行了以下交易：</p>
<ul>
<li>8 月 6 日星期二，Ingrid Delaet 卖出了 Neurocrine Biosciences 股票 273 股。股票平均售价为 147.70 美元，总价值为 40322.10 美元。</li>
</ul>
</div><h2>Neurocrine Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Neurocrine Biosciences 股价表现</h2>
</div><p>NBIX traded up $1.08 during midday trading on Thursday, reaching $147.77. 720,170 shares of the company's stock traded hands, compared to its average volume of 819,548. The firm has a fifty day moving average of $141.47 and a two-hundred day moving average of $138.88. The stock has a market capitalization of $14.87 billion, a price-to-earnings ratio of 40.55 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98.</p>
<ul>
<li>Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?</li>
</ul>
<div class="lb-trans"><p>NBIX 周四午盘交易上涨 1.08 美元，报价 147.77 美元。公司股票交易量为 720,170 股，相比平均交易量 819,548 股。该公司的 50 天移动平均价为 141.47 美元，200 天移动平均价为 138.88 美元。该股市值为 148.7 亿美元，市盈率为 40.55，β系数为 0.37。Neurocrine Biosciences, Inc.的 52 周最低价为 103.63 美元，52 周最高价为 157.98 美元。</p>
<ul>
<li>在强劲的第三季度报告后，中型市值的 Neurocrine Biosciences 值得买入吗？</li>
</ul>
</div><p>Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company's revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 EPS. Sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current year.</p>
<div class="lb-trans"><p>Neurocrine Biosciences（纳斯达克股票代码：NBIX）于 8 月 1 日星期四发布了季度财报。公司报告该季度每股收益为 0.63 美元，低于分析师预期的 1.15 美元（低 0.52 美元）。该季度营收为 5.902 亿美元，超过预期的 5.4598 亿美元。Neurocrine Biosciences 的净利润率为 16.00%，净资产收益率为 14.86%。公司该季度的营收同比增长 30.4%。在去年同期，公司每股收益为 0.95 美元。卖方分析师预测，Neurocrine Biosciences, Inc.今年将实现每股收益 4.22 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RFP Financial Group LLC grew its stake in shares of Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after buying an additional 149 shares during the last quarter. Mather Group LLC. purchased a new stake in Neurocrine Biosciences during the 1st quarter valued at $26,000. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $28,000. Lindbrook Capital LLC boosted its stake in Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company's stock valued at $28,000 after purchasing an additional 96 shares during the last quarter. Finally, Innealta Capital LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 92.59% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该公司的持股进行了调整。RFP Financial Group LLC 在第一季度将其对 Neurocrine Biosciences 的持股增加了 346.5%。RFP Financial Group LLC 现在拥有该公司股票 192 股，价值 26000 美元，上季度购入了额外的 149 股。Mather Group LLC 在第一季度购入了新的 Neurocrine Biosciences 股票，价值 26000 美元。Ashton Thomas Private Wealth LLC 在第二季度购入了新的 Neurocrine Biosciences 股票，价值 28000 美元。Lindbrook Capital LLC 在第四季度将其对 Neurocrine Biosciences 的持股增加了 85.0%。Lindbrook Capital LLC 现在拥有该公司股票 209 股，价值 28000 美元，上季度购入了额外的 96 股。最后，Innealta Capital LLC 在第二季度购入了新的 Neurocrine Biosciences 股票，价值 30000 美元。对冲基金和其他机构投资者拥有该公司股票的 92.59%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>NBIX has been the subject of several recent analyst reports. Oppenheimer boosted their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, August 2nd. JPMorgan Chase &amp; Co. lifted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, August 7th. Wedbush reaffirmed an &#34;outperform&#34; rating and set a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Morgan Stanley lifted their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, July 12th. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, July 25th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $158.68.</p>
<div class="lb-trans"><p>NBIX 近期成为多家分析师关注的对象。Oppenheimer 将 Neurocrine Biosciences 的目标股价从 216.00 美元上调至 219.00 美元，并在 8 月 2 日星期五的研究报告中给予该股票 “表现优异” 评级。摩根大通将 Neurocrine Biosciences 的股票价格目标从 173.00 美元上调至 181.00 美元，并在 8 月 7 日星期三的研究报告中给予该股票 “超配” 评级。Wedbush 在 5 月 29 日星期三的研究报告中重申了对 Neurocrine Biosciences 的 “表现优异” 评级，并设定了 152.00 美元的股价目标。摩根士丹利将 Neurocrine Biosciences 的股票价格目标从 160.00 美元上调至 170.00 美元，并在 7 月 12 日星期五的研究报告中给予该股票 “超配” 评级。最后，康泰纳菲茨重申了对 Neurocrine Biosciences 的 “超配” 评级，并在 7 月 25 日星期四的研究报告中设定了 155.00 美元的股价目标。六位研究分析师对该股票给予持有评级，十六位给予买入评级，两位给予强烈买入评级。根据 MarketBeat 的数据，Neurocrine Biosciences 目前的共识评级为 “中度买入”，共识目标股价为 158.68 美元。</p>
</div><p><strong>Get Our Latest Research Report on Neurocrine Biosciences</strong></p>
<div class="lb-trans"><p>获取我们关于 Neurocrine Biosciences 的最新研究报告</p>
</div><h2>Neurocrine Biosciences Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Neurocrine Biosciences 公司简介</h2>
</div><p>Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.</p>
<div class="lb-trans"><p>Neurocrine Biosciences, Inc.是一家在美国和国际市场上为神经、神经内分泌和神经精神疾病研发和销售药物的公司。该公司的产品包括用于迟发性运动障碍和与亨廷顿病相关的舞蹈症的 INGREZZA；用于肾上腺功能不全的 ALKINDI；用于经典先天性肾上腺增生的 Efmody 胶囊；用于子宫内膜异位症的 Orilissa 片剂；以及用于治疗子宫肌瘤的 Oriahnn 胶囊。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Neurocrine Biosciences</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票胜过 Neurocrine Biosciences</li>
<li>什么是股息？购买最佳股息股票</li>
<li>迈克尔·伯里的阿里巴巴赌注及其对整个市场的影响</li>
<li>风险承受能力，一刀切并不适合所有人</li>
<li>杰夫·布朗的 Exegesis AI 股票推荐</li>
<li>在 52 周最低点找到并盈利交易股票</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔哈撒韦买入了 Ulta 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=NBIX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 narrative science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ ⭕ [URGENT] Buy Alert just triggered (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ ⭕ [紧急] 刚刚触发购买警报（来自市场幕后）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9186&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Neurocrine Biosciences right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资神经分泌生物科学（Neurocrine Biosciences）？</h2>
</div><p>Before you consider Neurocrine Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资神经分泌生物科学之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票... 而神经分泌生物科学并不在这个名单上。</p>
</div><p>While Neurocrine Biosciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管神经分泌生物科学目前在分析师中有一个 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

英格丽德·德莱特出售了 7,143 股神经分泌生物科学公司（NASDAQ:NBIX）的股票